Roth Capital Partners raised its price target for IRadimed (NASDAQ:IRMD) to $35 from $26 after updating its forward financial forecasts. The stock closed at $31.40 on Sept. 19. IRadimed is the world’s first and...

H.C. Wainwright initiated coverage of AVROBIO (NASDAQ:AVRO) with a “buy” rating and $47 price target. The stock closed at $39.63 on Sept. 13. AVROBIO is pioneering the development of lentiviral gene therapies as a...

H.C. Wainwright raised its price target for Mersana Therapeutics (NASDAQ:MRSN) to $23 from $16 after the company disclosed plans to reinstate dosing of new patients following the FDA decision to lift the partial...

Stifel initiated coverage of UroGen Pharma (NASDAQ:URGN) with a “buy” rating and $70 price target. The stock closed at $43.90 on Sept. 12. “We think UroGen offers investors an opportunity to own a company with a late...

Ladenburg Thalmann launched coverage of Rocket Pharmaceuticals (NASDAQ:RCKT) with a “buy” rating and $30 price target. The stock closed at $23.96 on Sept. 12. Rocket is developing potentially curative first-in-class...

Stifel launched coverage of Rhythm Pharmaceuticals (NASDAQ:RYTM) with a “hold” rating and $36 price target, saying the risk/reward for the shares is pretty balanced at current levels. The stock closed at $30.77 on Sept...

Stifel initiated coverage of Vanda Pharmaceuticals (NASDAQ:VNDA) with a “buy” rating and $30 price target. The stock closed at $18.45 on Sept. 12. “We like the near-term catalyst path for Vanda shares as we believe...

J.P. Morgan launched coverage of ObsEva SA (NASDAQ:OBSV) with an “overweight” rating and a price target of $29 at the end of 2019. The stock closed at $14.40 on Sept. 12. “We view ObsEva as an underappreciated, emerging...

Ladenburg Thalmann initiated coverage of Arch Therapeutics (OTCQB:ARTH) with a “buy” rating and price target of $1.25. The stock closed at 46 cents on Sept. 11. The company is developing a novel hemostat to control skin...

Ladenburg Thalmann launched coverage of Novus Therapeutics (NASDAQ:NVUS) with a “buy” rating and $12 price target. The stock closed at $4.53 on Sept. 10. Novus is developing a novel treatment for otitis media (OM)...

H.C. Wainwright raised its price target for Avid Bioservices (NASDAQ:CDMO) to $11 from $6, saying the company’s business development continues to ramp up and reap rewards. The stock closed at $7.17 on Sept. 10. Avid is...

H.C. Wainwright initiated coverage of Melinta Therapeutics (NASDAQ:MLNT) with a “buy” rating and $14 price target. The stock closed at $4.30 on Sep. 10. Melinta is focused on its four marketed drugs, especially its two...

Ladenburg Thalmann launched coverage of Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a “buy” rating and $6.25 price target. The stock closed at $1.43 on Sept. 6. “We believe CYC065, the company’s CDK 2/9 inhibitor, has...

Roth Capital Partners initiated coverage of Obalon Therapeutics (NASDAQ:OBLN) with a “buy” rating and $6 price target. The stock closed at $2.91 on Sept. 5. Obalon offers the Obalon Balloon System, the first and only...

Piper Jaffray resumed coverage of Bovie Medical (NYSE American:BVX) with an “overweight” rating and $8 price target after the company completed the sale of its core business. The stock finished at $6.14 on Sept. 5...

H.C. Wainwright lowered its price target for Histogenics (NASDAQ:HSGX) to $2 from $3.50, but maintained its “buy” rating, after the company missed its primary endpoint in a Phase 3 study of NeoCart for knee cartilage...

Roth Capital Partners launched coverage of Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a “buy” rating and $8 price target. The stock closed at $1.57 on September 4. “We believe that Cyclacel, its clinical CDK inhibitor...

Analysts at BTIG and Ladenburg Thalmann initiated coverage of Vaccinex (NASDAQ:VCNX) with “buy” ratings and price targets of $20 and $22, respectively. The stock closed at $9.99 on August 31. Vaccinex, which went public...

H.C. Wainwright initiated coverage of Immune Design (NASDAQ:IMDZ) with a “buy” rating and $11 price target. The stock closed at $3.45 on August 29. “Based on our broad and long-term coverage of cancer immunotherapy, we...

H.C. Wainwright raised its price target for Sophiris Bio (NASDAQ:SPHS) to $10 from $4.30, citing autopsy results that found a patient deathin its Phase 2b trial for the treatment of localized prostate cancer was not...

H.C. Wainwright initiated coverage of Coherus BioSciences (NASDAQ:CHRS) with a “buy” rating and $28 price target. The stock closed at $19.75 on August 27. “We expect approval of UDENCYA, CHS-1701, in both the U.S. and...

Stifel upgraded Capital Senior Living (NYSE:CSU) to “hold” from “sell” but maintained its price target of $8.50, saying the shares have overshot its fair value estimates. The stock closed at $8.34 on August 23. “We...